Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CNTN | PRESS-RELEASE | neutral | 4/10 | Canton Strategic Holdings reported its first-ever operating revenue of $1.5M for Q2 2026, driven by its Canton Network S | Aug 14, 2026 |
| SLXN | PRESS-RELEASE | bearish | 5/10 | Silexion Therapeutics reported Q2 2026 net loss of $3.6M (vs $2.5M a year ago) and EPS of -$8.50, far below the -$2.12 c | Aug 14, 2026 |
| VVOS | PRESS-RELEASE | neutral | 1/10 | Vivos Therapeutics, Inc announced it will report its Q2 2026 results on August 14, 2026. | Aug 14, 2026 |
| USDE | PRESS-RELEASE | neutral | 3/10 | StablecoinX reported its first quarter as a public company following the June 25, 2026 business combination with TLGY Ac | Aug 14, 2026 |
| BCAX | PRESS-RELEASE | neutral | 2/10 | Bicara Therapeutics announced an inducement stock option grant to new CFO Jennifer Larson, effective August 12, 2026, as | Aug 14, 2026 |
| PATK | PRESS-RELEASE | neutral | 2/10 | Patrick Industries declared a quarterly cash dividend of $0.47 per share, payable September 8, 2026, to shareholders of | Aug 14, 2026 |
| CGCFU | PRESS-RELEASE | neutral | 2/10 | Cartesian Growth Corporation IV announced that holders of its IPO units may elect to separately trade the Class A ordina | Aug 14, 2026 |
| NMAD | PRESS-RELEASE | neutral | 3/10 | NOMAD Power Solutions (formerly LIXTE Biotechnology) filed its Q2 2026 10-Q and provided a business update. The filing r | Aug 14, 2026 |
| VTGN | PRESS-RELEASE | neutral | 4/10 | Vistagen reported Q1 FY2027 results with a net loss of $0.30 per share, beating consensus of -$0.36 by 16.7%, and revenu | Aug 14, 2026 |
| AIB | PRESS-RELEASE | bearish | 6/10 | AIB Data Centers reported Q2 2026 revenue of $2.9M (down 39% YoY, missing $3.7M consensus by 21%) and EPS of -$0.07 (mis | Aug 14, 2026 |
| CYCU | PRESS-RELEASE | mixed | 5/10 | Cycurion reported Q2 2026 results that beat consensus estimates on both revenue ($3.76M vs $3.62M) and EPS (-$0.41 vs -$ | Aug 14, 2026 |
| DTST | PRESS-RELEASE | neutral | 4/10 | Data Storage Corp. reported Q2 2026 revenue of $358.5K (up 9.3% YoY but missing the $400K consensus) and a net loss of $ | Aug 14, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 6/10 | TOMI Environmental Solutions reported Q2 2026 revenue of $2.25M (+118% YoY) and EPS of $(0.05), beating consensus of $(0 | Aug 14, 2026 |
| CLNN | PRESS-RELEASE | mixed | 7/10 | Clene reported Q2 2026 results with a GAAP net loss of $13.4M ($1.08/share), significantly missing the $0.37 consensus d | Aug 14, 2026 |
| MBRX | PRESS-RELEASE | mixed | 6/10 | Moleculin Biotech reported Q2 2026 results with a net loss of -$1.40/share, beating the -$1.55 consensus, and highlighte | Aug 14, 2026 |
| ZEO | PRESS-RELEASE | bearish | 6/10 | Zeo Energy reported Q2 2026 revenue of $16.2M, down 10.7% YoY, and an Adjusted EBITDA loss of $(2.1)M vs a profit of $1. | Aug 14, 2026 |
| DUOT | PRESS-RELEASE | neutral | 1/10 | Duos Technologies Group, Inc announced it will report its Q2 2026 results on August 17, 2026. | Aug 14, 2026 |
| OBAI | PRESS-RELEASE | mixed | 5/10 | Our Bond reported Q2 2026 revenue of $2.1M, down ~9% YoY from $2.3M, and a net loss of $4.8M, a 28% sequential improveme | Aug 14, 2026 |
| ALLR | PRESS-RELEASE | neutral | 4/10 | Allarity Therapeutics reported Q2 2026 results with a net loss of $3.4M (vs $2.3M in Q2 2025), driven by higher interest | Aug 14, 2026 |
| RMIX | PRESS-RELEASE | bearish | 6/10 | Suncrete (RMIX) reported Q2 2026 revenue of $97.2M, up 146% YoY, but posted a net loss of $37.1M versus a $325K loss a y | Aug 14, 2026 |
| HELP | PRESS-RELEASE | bullish | 7/10 | Helus Pharma reported Q4 fiscal 2026 (period ended March 31, 2026) EPS of -$1.17, beating consensus of -$1.38 by 15.5%. | Aug 14, 2026 |
| BENF | PRESS-RELEASE | mixed | 5/10 | Beneficient reported fiscal Q1 2027 results with GAAP EPS of -$0.47 (vs -$57.55 prior quarter) and GAAP revenues of $12. | Aug 14, 2026 |
| MLSS | PRESS-RELEASE | neutral | 4/10 | Milestone Scientific reported Q2 2026 revenue of $2.8M (+22% YoY), in line with consensus, and EPS of -$0.01, matching e | Aug 14, 2026 |
| CSPI | PRESS-RELEASE | bearish | 5/10 | CSPI reported a fiscal Q3 2026 net loss of $0.09 per share on revenue of $14.4M, down 6.8% YoY from $15.4M, as Technolog | Aug 14, 2026 |
| REPL | PRESS-RELEASE | bullish | 7/10 | Replimune reported a modest EPS beat ($-0.72 vs $-0.77 consensus) for Q1 FY2026, but the headline is the FDA accelerated | Aug 14, 2026 |
| SURG | PRESS-RELEASE | mixed | 6/10 | SurgePays reported Q2 2026 GAAP net income of $1.29M ($0.05 EPS), a sharp reversal from a $7.08M loss in Q2 2025, driven | Aug 14, 2026 |
| QNCX | PRESS-RELEASE | bullish | 6/10 | Quince Therapeutics reported Q2 2026 results highlighting a strengthened balance sheet with $116M cash following the Orp | Aug 14, 2026 |
| GTBP | PRESS-RELEASE | bearish | 5/10 | GT Biopharma reported Q2 2026 EPS of -$0.11, missing consensus of -$0.08 by 37.5%, with no revenue. Cash runway of $5.1M | Aug 14, 2026 |
| PMVP | PRESS-RELEASE | bullish | 6/10 | PMV Pharma reported Q2 2026 EPS of -$0.34, beating the -$0.38 consensus by 10.5%, and completed enrollment for the prima | Aug 14, 2026 |
| EVAX | PRESS-RELEASE | neutral | 1/10 | Evaxion announced it will report its Q2 2026 results on August 20, 2026. | Aug 14, 2026 |